Sugi Predict

Sugi Predict / Compounds / SCHEMBL1114650

SCHEMBL1114650

SCHEMBL1114650

O=C(O)CCCCc1ccc(Br)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.66
▸ RXFP1 Q9HBX9 1/20 0.66
▸ HDAC2 Q92769 2/20 0.59
▸ HDAC3 O15379 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ ADRA1A P35348 1/20 0.59
▸ HDAC4 P56524 1/20 0.59
▸ SLC6A3 Q01959 1/20 0.59
▸ HDAC1 Q13547 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ HDAC7 Q8WUI4 1/20 0.59
▸ HDAC10 Q969S8 1/20 0.59
▸ HDAC11 Q96DB2 1/20 0.59
▸ HDAC8 Q9BY41 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ HDAC9 Q9UKV0 1/20 0.59
▸ HDAC5 Q9UQL6 1/20 0.59
▸ FFAR1 O14842 2/20 0.56
▸ FFAR4 Q5NUL3 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16136610 0.98 MAPT (0.69) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL10276971 0.98 MAPT (0.69) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL29831093 0.98 MAPT (0.69) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL9859814 0.98 MAPT (0.69) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL25176127 0.98 MAPT (0.69) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL1857558 0.94 HDAC1 (0.67) MAPTRXFP1HDAC2HDAC3MAPK1
Hydrochloric Acid SCHEMBL3866368 0.92 SMN1; SMN2 (0.64) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL7065645 0.89 MAPT (0.79) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL11756466 0.89 HDAC2 (0.60) MAPTRXFP1HDAC2HDAC3MAPK1
SCHEMBL9671779 0.87 MAPT (0.83) MAPTRXFP1HDAC2HDAC3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107406-A1 p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF Design Therapeutics, Inc. (US) 2026-05-21 — — WO disclosed
CN-109896918-B Unsaturated carbonyl compound and preparation method and application thereof 北京大学深圳研究生院 2022-05-06 — — CN disclosed
EP-3191453-B1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2019-10-23 — — EP disclosed
EP-3191453-B1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2019-10-23 — — EP disclosed
US-10336684-B2 Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators BRISTOL=MYERS SQUIBB COMPANY (US) 2019-07-02 — — US disclosed
US-10336684-B2 Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators BRISTOL=MYERS SQUIBB COMPANY (US) 2019-07-02 — — US disclosed
US-20180319737-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-11-08 — — US disclosed
US-20170327457-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-11-16 — — US disclosed
US-20170327457-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-11-16 — — US disclosed
US-20170327457-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-11-16 — — US disclosed
CN-101389613-A Macrocyclic factor viia inhibitors useful as anticoagulants BRISTOL MYERS SQUIBB CO (US) 2009-03-18 — — CN disclosed
EP-1971582-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2008-09-24 — — EP disclosed
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 — — US disclosed
WO-2007076431-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-05 — — WO disclosed
CN-1909904-A 4-aryl piperidines LUNDBECK & CO AS H (DK) 2007-02-07 — — CN disclosed
EP-1708704-A2 4-ARYL PIPERIDINES H.Lundbeck A/S (DK) 2006-10-11 — — EP disclosed
WO-2005069834-A2 4-ARYL PIPERIDINES H. LUNDBECK A/S (DK) 2005-08-04 — — WO disclosed
US-20050154022-A1 4-aryl piperidines H. LUNDBECK A/S 2005-07-14 — — US disclosed
EP-0673248-A1 POTASSIUM CHANNEL ACTIVATORS FOR USE IN THERAPY SMITHKLINE BEECHAM PLC (GB) 1995-09-27 — — EP disclosed
WO-1994013292-A1 POTASSIUM CHANNEL ACTIVATORS FOR USE IN THERAPY SMITHKLINE BEECHAM PLC (GB) 1994-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327457-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS GPR88, GPR55, GPR180 MAPT 4401/4885RXFP1 387/4885HDAC2 561/4885
US-20180319737-A1 PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS GPR88, GPR55, GPR180 MAPT 4401/4885RXFP1 387/4885HDAC2 561/4885
US-10336684-B2 Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators GPR88, GPR55, GPR180 MAPT 4401/4885RXFP1 387/4885HDAC2 561/4885
US-20050154022-A1 4-aryl piperidines MCHR1, MCHR2, MC1R MAPT 3500/4885RXFP1 80/4885HDAC2 1955/4885
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F12, F7, F2 MAPT 1936/4885RXFP1 863/4885HDAC2 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.